1GERMING U,KUNDGEN A,GATTERMANN N.Risk assessment in chronic myelomonocytic leuke-mia[J].Leuk Lymphoma,2004,45:1311-1318.
2OKI Y,JELINEK J,SHEN L,et al.Induction of hy-pomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leu-kemia[J].Blood,2008,111:2382-2384.
3CHESON B D,GREENBERG P L,BENNETT J M,et al.Clinical application and proposal for modification of the International Working Group(IWG)response criteria in myelodysplasia[J].Blood,2006,108:419-425.
4VALENT P,HORNY H P,BENNETT J M,et al.Definitions and standards in the diagnosis and treat-ment of the myelodysplastic syndromes:Consensus statements and report from a working conference[J].Leuk Res,2007,31:727-736.
6WIJERMANS P W,RUTER B,BAER M R,et al.Ef-ficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia[J].Leuk Res,2008,32:587-591.
7KANTARJIAN H,OKI Y,GARCIA-MANERO G,et al.Results of a randomized study of3schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52-57.
8IASTREBNER M,JANG J H,NUCIFORA E,et al.Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia:Argentinian/South Korean multi-institutional clinical experience[J].Leuk Lym-phoma,2010,51:2250-2257.
9JABBOUR E,GARCIA-MANERO G,BATTY N,et al.Outcome of patients with myelodysplastic syn-drome after failure of decitabine therapy[J].Cancer,2010,116:3830-3834.
同被引文献46
1Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management[ J ] . Hematol,2012,87 ( 6): 610-619.
2Akiyxnx N, Ohwxdx A, Kajiwara K, et al. Granulytic sarcoma of the colon in chronic myclomonocytic lcukemia[ J ] . Rinsho Ketsucki, 2002,43 ( 10 ): 937-942.
3Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia [ J ]. Cancer, 2007,109 ( 4): 713-717.
4Braun T, Droin N, hzykson R, et al. A phase II study of deeitahine in advanced chronic myelomonocytie leukemia ( CMML ) [ J ]. Leukemia Research, 2011, 35 : 563-564.
5Wijermans P, Luhhert M, Verhoef IN, et al. An epigenetic approach to the treatment of advanced MDS: the experience with the DNA demethylating agent 5-aza-2-1eoxycytidine ( Deeitabine )in 177 patients[ J ]. Ann Hematol, 2005,84( Buppl 1 ): 9-17.
6Wolfromm A, Dreyfus F, Vey N, et al. Treatment of advanced CMML by azacitidine ( AZA )in a compassionate program. The GFM experience in 38 patients[ J ]. Leukemia Research ,2011, 35 : 540.
8Lubbert M,Suciu S,Baila L. Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].Clinical Oncology,2011,(15):1987-1996.
9张之南;沈悌.血液学诊断及疗效标准[S]北京:科学出版社,2006279-281.
10Saba HI. Decitabine in the treatment of myelodysplastic syndromes[J].Ther Clin Risk Manag,2007,(05):807-817.
